(UroToday.com) The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting’s kidney and bladder cancer poster discussion included a discussant presentation by Dr. Anil Kapoor addressing unanswered questions in the management of advanced renal cell carcinoma. Dr. Kapoor notes that there are many unanswered questions, including the following:
(UroToday.com) The American Society of Clinical Oncology (ASCO) 2021 Annual Meeting featured a session discussing oligometastases in prostate cancer, and specifically how to rationally incorporate metastasis-directed therapy in your practice. The chair/moderator for this session was Dr. Howard M. Sandler from Cedars-Sinai Medical Center, and the panel included Dr. Phuoc Tran from Johns Hopkins University School of […]
(UroToday.com) Radiation therapy to the prostate bed and pelvic nodes with short-term androgen deprivation therapy is considered a standard of care salvage therapy paradigm for prostate cancer patients with post-prostatectomy biochemical recurrence. Fluciclovine-PET/CT imaging is FDA-approved in this setting, with improved accuracy for detection of metastases not identified with conventional imaging. Given PET’s greater sensitivity and […]
(UroToday.com) Biochemical recurrence is a clinical challenge in prostate cancer patients with impact on definition of subsequent therapies. The use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) presents better accuracy than standard imaging practice. This phase 3, prospective, multicenter, international study evaluates the diagnostic performance and clinical impact of PSMA-PET/CT in evaluating biochemical […]
(UroToday.com) Immunotherapy-based combination therapies are standard of care for metastatic RCC in the frontline setting. However, limited data is available on the role of cytoreductive nephrectomy prior to immunotherapy-based combination therapies in patients with metastatic RCC. At the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, Dr. Jaleh Fallah and colleagues presented the results of their […]
(UroToday.com) There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations of […]
(UroToday.com) Many patients with renal cell carcinoma (RCC) present with de novo metastatic disease and an appreciable proportion of patients with an initial diagnosis of localized disease subsequently develop advanced or metastatic RCC after surgical treatment. Metastasis to the central nervous system is reported in 3-17% of patients with advanced disease. Patients with untreated brain metastasis […]
To assess the mid-term efficacy and safety of anterior urethroplasty using an autologous tissue-engineered oral mucosa graft (MukoCell® ). The data of 77 patients with anterior urethral strictures undergoing treatment with MukoCell® at a tertiary center from June 2016 to May 2019 were analyzed.
To perform a systematic review to assess and compare the efficacy and safety of all urethral bulking agents (UBAs) available for the treatment of stress urinary incontinence (SUI) in women. This systematic review was conducted in accordance with the PRISMA guideline.
To present a summary of the 2021 version of the European Association of Urology (EAU) guidelines on management of male urethral stricture disease. The panel performed a literature review on these topics covering a time frame between 2008 and 2018, and used predefined inclusion and exclusion criteria for the literature to be selected.
